title: Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
abstract: Limited studies indicate a possible association of 5'-UTR thymidylate synthase enhancer region polymorphism and treatment outcome in patients medicated with 5-fluorouracil (5-FU). The study was designed to verify the relationship in patients with colorectal cancer (CRC), a Polish population that received 5-FU-based adjuvant chemotherapy. The study analyzed 145 Astler-Coller B2 and C CRC patients. Genotyping for a variable number of tandem repeats and G to C single-nucleotide polymorphism in the 5'-UTR of the thymidylate synthase (TS) gene was carried out. TS genotypes were classified into high expression (high TS) and low expression types (low TS). High TS was found in 22.8% of patients. The right-side tumors were more frequently associated with high TS than the left-side tumors (p=0.024). High TS was only found in 9.3% of rectal tumors, but in 29.7% of colon cancers (p=0.0042). Disease-free survival after 20 months (DFS 20) was longer in subjects with low TS than in high TS (p=0.043). Patients who underwent chemotherapy had longer DFS 20 in the low TS than in the high TS subgroup (p=0.051). The low TS was found to be an independent good prognostic factor for DFS 20 in the whole group as well as in the subgroup treated with chemotherapy (p=0.024 and p=0.034, respectively). Patients with low TS did not show any differences in DFS 20 whether they were treated with adjuvant chemotherapy or not. Proximal CRC tumors are characterized by higher TS expression genotypes than distal tumors, and are at significantly greater risk of early recurrence during the first 20 months after surgery.
authors: 1 Department of Oncology, Pomeranian Medical University , Szczecin, Poland .
authors: Violetta
authors: V
authors: Sulzyc-Bielicka
authors: Dariusz
authors: D
authors: Bielicki
authors: Agnieszka
authors: A
authors: Binczak-Kuleta
authors: Mariusz
authors: M
authors: Kaczmarczyk
authors: Wiesława
authors: W
authors: Pioch
authors: Anna
authors: A
authors: Machoy-Mokrzynska
authors: Andrzej
authors: A
authors: Ciechanowicz
authors: Magdalena
authors: M
authors: Gołębiewska
authors: Marek
authors: M
authors: Drozdzik
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality* / Q000601:surgery; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D011044:Poland / Q000453:epidemiology; D011110:Polymorphism, Genetic; D012008:Recurrence; D016019:Survival Analysis; D013940:Thymidylate Synthase / Q000235:genetics*
chemical_list: D013940:Thymidylate Synthase; D005472:Fluorouracil
references: Pharmacogenetics. 2004 May;14(5):319-27
references: 15115918
references: J Clin Oncol. 1997 Oct;15(10):3223-9
references: 9336359
references: Int J Oncol. 2009 Jan;34(1):219-29
references: 19082493
references: Pharmacogenet Genomics. 2005 Oct;15(10):723-30
references: 16141798
references: J Int Med Res. 2010 Mar-Apr;38(2):484-97
references: 20515563
references: Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):958-62
references: 14578129
references: Oncol Rep. 2007 Jul;18(1):203-9
references: 17549369
references: Mol Cancer Ther. 2009 May;8(5):1000-7
references: 19383851
references: J Clin Oncol. 2002 Jun 15;20(12):2832-43
references: 12065560
references: Lancet. 2000 May 20;355(9217):1745-50
references: 10832824
references: J Clin Oncol. 2002 Apr 1;20(7):1721-8
references: 11919227
references: Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3769-74
references: 10097112
references: Br J Cancer. 2001 Sep 14;85(6):827-30
references: 11556832
references: Int J Colorectal Dis. 2005 Mar;20(2):94-102
references: 15309465
references: Genomics. 1999 Jun 15;58(3):310-2
references: 10373329
references: Front Biosci. 2004 Sep 01;9:2484-94
references: 15353301
references: J Clin Oncol. 2004 Feb 1;22(3):529-36
references: 14752076
references: Nat Clin Pract Gastroenterol Hepatol. 2009 Feb;6(2):108-20
references: 19153564
references: Int J Oncol. 2001 Aug;19(2):383-6
references: 11445856
references: Annu Rev Biochem. 1995;64:721-62
references: 7574499
references: Cancer Res. 2003 Jun 1;63(11):2898-904
references: 12782596
references: Oncology. 2002;62(2):167-74
references: 11914603
references: Cell Struct Funct. 1995 Jun;20(3):191-7
references: 7586009
references: Br J Cancer. 2000 Feb;82(3):560-7
references: 10682666
references: J Clin Oncol. 1989 Oct;7(10):1447-56
references: 2778478
references: Lancet. 2007 Dec 15;370(9604):2020-9
references: 18083404
references: Biochim Biophys Acta. 1977 Dec 23;473(2):73-92
references: 145246
references: BMC Cancer. 2006 Jun 05;6:150
references: 16753067
references: J Gastrointest Surg. 2002 May-Jun;6(3):331-7
references: 12022983
references: Gastroenterology. 2008 May;134(5):1296-310
references: 18471507
references: BMC Genomics. 2006 Apr 03;7:68
references: 16584549
references: Virchows Arch. 2009 Jun;454(6):695-702
references: 19444465
references: Langenbecks Arch Surg. 2004 Oct;389(5):405-13
references: 15309542
references: Cancer Cell. 2004 Apr;5(4):341-51
references: 15093541
references: Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3700-4
references: 14506161
references: J Clin Oncol. 2003 Jan 15;21(2):241-50
references: 12525515
references: Ann Oncol. 2001 Feb;12(2):239-44
references: 11300331
references: Cancer Res. 2003 Sep 15;63(18):6004-7
references: 14522928
references: Clin Cancer Res. 2003 Feb;9(2):786-91
references: 12576451
references: Clin Cancer Res. 2003 Sep 15;9(11):4116-24
references: 14519634